Floatz logo

Resmetirom

Cirrhosis Of Liver

Madrigal Pharmaceuticals, Inc.Small moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
81/ 100

Competitive context

133 Active assets in the Cirrhosis Of Liver cohort.

Asset / SponsorPhaseRating
Veruprevir
AbbVie
Phase 3A
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Normal Human Serum Albumin
King George's Medical University
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Resmetirom is also rated in:

metabolic dysfunction-associated steatohepatitisActive
BBB
Indicative · Phase 4
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
B
Indicative · Phase 3
62 / 100
View asset →
HIV infectious diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →